NCT01983124View on ClinicalTrials.gov

Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

September 30, 2015

Conditions
Malignant Melanoma Stage IV
Interventions
DRUG

Fotemustine + Vemurafenib

"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."

Trial Locations (2)

16132

Paola Queirolo, Genova

80131

"Istituto Nazionale per lo Studio e la Cura dei Tumori G.Pascale", Napoli

All Listed Sponsors
collaborator

Istituto Nazionale per lo Studio e la Cura dei Tumori

OTHER

lead

Paola Queirolo

OTHER

NCT01983124 - Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib | Biotech Hunter | Biotech Hunter